In collaboration with:
InnoSIGN is attending the Edinburgh Breast Cancer Special Symposium this Saturday, February 25th at the John McIntyre Conference Centre, Edinburgh, UK.
During this symposium our Clinical Operations Manager, Diederick Keizer, will present results of the OncoSIGNal pathway activity analysis performed on samples of the NEOLBC breast cancer randomized phase II trial performed under responsibility of the Borstkanker Onderzoek Groep (BOOG) in The Netherlands.
By using OncoSIGNal the authors observed that ER pathway activity in the tumor had decreased after two weeks neo-adjuvant letrozole treatment, but increased after switching to chemotherapy.
Are you at the EBCSS? Visit us at booth #B3.
To learn more about OncoSIGNal click here.
